CPC A61M 5/1723 (2013.01) [A61B 5/14532 (2013.01); A61B 5/14546 (2013.01); A61B 5/388 (2021.01); A61B 5/7225 (2013.01); A61B 5/7264 (2013.01); A61B 5/7282 (2013.01); A61N 1/36053 (2013.01); A61N 1/36139 (2013.01); A61N 7/00 (2013.01); A61B 2560/0214 (2013.01); A61B 2560/0238 (2013.01); A61N 2007/0026 (2013.01)] | 13 Claims |
1. A method for diagnosing or treating or monitoring symptoms in a subject with diabetes based on the subject's nerve activity, wherein the nerve activity consists of vagus nerve activity, comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, wherein the calibration phase precedes the real-time diagnostic, treatment or monitoring phase, and wherein
the calibration phase comprises correlating a plurality of nerve activity measurements from a chronically implanted recording electrode in the subject, wherein the nerve activity measurements consists of vagus nerve activity measurements, with a plurality of concurrent measurements of glucose levels in the blood of the subject to obtain a functional relationship between blood glucose levels and vagus nerve activity recorded from the chronically implanted recording electrode in the subject, wherein the blood glucose measurements during the calibration phase consist of one or more of blood glucose levels that fluctuate naturally in the subject and blood glucose levels that occur in response to administration of one or more of insulin, glucose and glucagon to the subject; and
the real-time diagnostic, treatment or monitoring phase comprises analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship between blood glucose levels and vagus nerve activity to initiate a treatment method, wherein the treatment method consists of one or more of administering insulin, glucose or glucagon to the subject, and applying acoustic energy stimulus to the subject.
|